Differential psychostimulant-induced activation of neural circuits in dopamine transporter knockout and wild type mice

Neuroscience

Volumn 118, Issue 2, 2003, Pages 297-310

  Trinh, J V ^a   Nehrenberg, D L ^b   Jacobsen, J P R ^a   Caron, M G ^a   Wetsel, W C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

ADHD; Drug abuse; Early immediate gene; Mutant mice

Indexed keywords

AMPHETAMINE; COCAINE; DOPAMINE TRANSPORTER; METHYLPHENIDATE; PROTEIN FOS; PSYCHOSTIMULANT AGENT;

AMYGDALOID NUCLEUS; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN TISSUE; CAUDATE NUCLEUS; CELL ACTIVATION; CINGULATE GYRUS; CONTROLLED STUDY; DENTATE GYRUS; DORSAL RAPHE NUCLEUS; DRUG EFFECT; FEMALE; FRONTAL CORTEX; GENE DISRUPTION; GLOBUS PALLIDUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KNOCKOUT MOUSE; LIMBIC CORTEX; MALE; MOUSE; NERVE CELL; NONHUMAN; NUCLEUS ACCUMBENS; OLFACTORY NUCLEUS; ORBITAL CORTEX; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PUTAMEN; SEPTUM PELLUCIDUM; STRIA TERMINALIS; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; VENTRAL TEGMENTUM;

EID: 0242500285     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(03)00165-9     Document Type: Article

References (61)

1. Amara S.G., Kuhar M.J. Neurotransmitter transporters recent progress . Annu Rev Neurosci. 16:1993;73-93.
2. Badiani A., Oates M.M., Day H.E.W., Watson S.J., Akil H., Robinson T.E. Amphetamine-induced behavior, dopamine release, and c-fos mRNA expression modulation by environmental novelty . J Neurosci. 18:1998;10579-10593.
3. Bannon M.J., Granneman J.G., Kapatos G. The dopamine transporter potential involvement in neuropsychiatric disorders . Bloom F.E., Kupfer D.J. Psychopharmacology: the fourth generation of progress. 1995;179-188 Raven Press, New York.
4. Carlsson A. Monoamines in the central nervous system a historical perspective . Meltzer H.Y. Psychopharmacology: the third generation of progress. 1987;359-366 Raven Press, New York.
5. Cook E.H. Jr, Stein M.A., Krasowski M.D., Cox N.J., Olkon D.M., Kieffer J.E., Leventhal B.L. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet. 56:1995;993-998.
6. Delfs J.M., Zhu Y., Druhan J.P., Aston-Jones G. Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature. 403:2000;430-434.
7. DiChiara G, Tanda GL, Frau R, Carboni E (1992) Heterologous monoamine reuptake: lack of transporter specificity of neuron-specific carriers. Neurochem Int 20(suppl):231S-235S.
8. Dong H.W., Petrovich G.D., Swanson L.W. Topography of projections from amygdala to bed nuclei of the stria terminalis. Brain Res Rev. 38:2001;192-246.
9. Duncan G.E., Knapp D.J., Breese G.R. Neuroanatomical characterization of Fos induction in rat behavioral models of anxiety. Brain Res. 713:1996;79-91.
10. Engber T.M., Koury E.J., Dennis S.A., Miller M.S., Contreras P.C., Bhat R.V. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett. 241:1998;95-98.
11. Everitt B.J., Parkinson J.A., Olmstead M.C., Arroyo M., Robledo P., Robbins T.W. Associative processes in addiction and reward the role of amygdala-ventral striatal subsystems . Ann NY Acad Sci. 877:1999;412-438.
12. Feldman R.S., Meyer J.S., Quenzer L.F. Principles of neuropsychopharmacology. 1997;277-344 Sinauer Associates, Sunderland, MA.
13. Findling R.L., Dogin J.W. Psychopharmacology and ADHD children and adolescents . J Clin Psychiatry. 59:(suppl):1998;42-49.
14. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates. 1997;Academic Press, San Diego.
15. Freed C., Revay R., Vaughan R.A., Kriek E., Grant S., Uhl G.R., Kuhar M.J. Dopamine transporter immunoreactivity in rat brain. J Comp Neurol. 359:1995;340-349.
16. Fuxe K., Agnati L.F., Kalia M., Goldstein M., Andersson K., Härfstrand A. Dopaminergic systems in the brain and pituitary. Flückinger E., Müller E.E., Thorner M.O. Basic and clinical aspects of neuroscience: the dopaminergic system. 1985;11-25 Springer-Verlag, Berlin.
17. Gainetdinov R.R., Jones S.R., Fumagalli F., Wightman R.M., Caron M.G. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res Rev. 26:1998;148-153.
18. Gainetdinov R.R., Mohn A.R., Bohn L.M., Caron M.G. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proc Natl Acad Sci USA. 98:2001;11047-11054.
19. Gainetdinov R.R., Wetsel W.C., Jones S.R., Levin E.D., Jaber M., Caron M.G. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science. 283:1999;397-401.
20. Garris P.A., Ciolkowski E.L., Pastore P., Wightman R.M. Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J Neurosci. 14:1994;6084-6093.
21. Gatley S.J., Pan D., Chen R., Chaturvedi G., Ding Y.-S. Affinities of methylphenidate derivatives for dopamine, norepinephrine, and serotonin transporters. Life Sci. 58:1996;231-239.
22. Gill M., Daly G., Heron S., Hawi Z., Fitzgerald M. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol Psychiatry. 2:1997;311-313.
23. Giros B., Caron M.G. Molecular characterization of the dopamine transporter. Trends Pharmacol Sci. 14:1993;43-49.
24. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 379:1996;606-612.
25. Graybiel A.M., Moratella R., Robertson H.A. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc Natl Acad Sci USA. 87:1990;6912-6916.
26. Heimer L., Zahm D.S., Alheid G.F. Basal ganglia. In: The rat nervous system, 2nd edition (Paxinos G, ed), pp. 579:1994;628. San Diego: Academic Press.
27. Hoffman B.J., Hansson S.R., Mezey E., Palkovits M. Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front Neuroendocrinol. 19:1998;187-231.
28. Hope B.T., Nye H.E., Kelz M.B., Self D.W., Iadarola M.J., Nakabeppu Y., Duman R.S., Nestler E.J. Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron. 13:1994;1235-1244.
29. Ishida Y., Todaka K., Kuwahara I., Ishizuka Y., Hashiguchi H., Nishimori T., Mitsuyama Y. Methamphetamine induces Fos expression in the striatum and the substantia nigra pars reticulata in a rat model of Parkinson's disease. Brain Res. 809:1998;107-114.
30. Jackson D.M., Westlind-Danielsson A. Dopamine receptors molecular biology, biochemistry and behavioural aspects . Pharm Ther. 64:1994;291-370.
31. Jacobsen L.K., Hamburger S.D., Van Horn J.D., Vaituzis A.C., McKenna K., Frazier J.A., Gordon C.T., Lenane M.C., Rapoport J.L., Zametkin A.J. Cerebral glucose metabolism in childhood onset schizophrenia. Psychiatry Res. 75:1997;131-144.
32. Johansson B., Lindstrom K., Fredholm B.B. Differences in the regional and cellular localization of c-fos mRNA induced by amphetamine, cocaine and caffeine in the rat. Neuroscience. 59:1994;837-849.
33. Jones S.R., Gainetdinov R.R., Hu X.-T., Cooper D.C., Wightman R.M., White F.J., Caron M.G. Loss of autoreceptor functions in mice lacking the dopamine transporter. Nature Neurosci. 2:1999;649-655.
34. Jones S.R., Gainetdinov R.R., Jaber M., Giros B., Wightman R.M., Caron M.G. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA. 95:1998;4029-4034.
35. Kandel E.R., Schwartz J.H., Jessell T.M. Principles of neural science. 4th edition:2000;853-867 McGraw-Hill, New York.
36. Lee Y.L., Hamamura T., Ohashi K., Miki M., Fujiwara Y., Kuroda S. Carbamazepine suppresses methamphetamine-induced fos expression in a regionally specific manner in the rat brain possible neural substrates responsible for antimanic effects of mood stabilizers . Neuropsychopharmacology. 22:2000;530-537.
37. Lin J.S., Hou Y., Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA. 93:1996;14128-14133.
38. Lowry D.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem. 193:1951;265-275.
39. Mannuzza S., Gittelman R. The adolescent outcome of hyperactive girls. Psychiatr Res. 13:1994;19-29.
40. Mason A., Banerjee S., Eapen V., Zeitlin H., Robertson M.M. The prevalence of Tourette syndrome in a mainstream school population. Dev Med Child Neurol. 40:1998;292-296.
41. Moratalla R., Elibol B., Vallejo M., Graybiel A.M. Network-level changes in expression of inducible Fos-Jun proteins in the striatum during chronic cocaine treatment and withdrawal. Neuron. 17:1996;147-156.
42. Morgan J.I., Curran T. Stimulus-transcription coupling in the nervous system involvement of the inducible proto-oncogenes fos and jun . Annu Rev Neurosci. 14:1991;421-451.
43. Paladini C.A., Fiorillo C.D., Morikawa H., Williams J.T. Amphetamine selectively blocks inhibitory glutamate transmission in dopamine neurons. Nat Neurosci. 4:2001;275-281.
44. Pifl C., Giros B., Caron M.G. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinum. J Neurosci. 13:1993;4246-4253.
45. Pontieri F.E., Zocchi A., Orzi F. Mapping of functional changes associated with administration of substances of abuse in the rat. Funct Neurol. 13:1998;311-326.
46. Porrino L.J., Domer F.R., Crane A.M., Sokoloff L. Selective alterations in cerebral metabolism within the mesocorticolimbic dopaminergic system produced by acute cocaine administration in rats. Neuropsychopharmacology. 1:1988;109-118.
47. Reith M.E.A., Xu C., Chen N.-H. Pharmacology and regulation of the neuronal dopamine transporter. Eur J Pharmacol. 324:1997;1-10.
48. Rocha B.A., Fumagalli F., Gainetdinov R.R., Jones S.R., Ator R., Giros B., Miller G.W., Caron M.G. Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci. 1:1998;132-137.
49. Rodriguez J.J., Montaron M.F., Aurousseau C., LeMoal M., Abrous D.N. Effects of amphetamine and cocaine treatment on c-Fos, Jun-B, and Krox-24 expression in rates with intrastriatal dopaminergic grafts. Exp. Neurol. 159:1999;139-152.
50. Roth R.H., Elsworth J.D. Biochemical pharmacology of midbrain dopamine neurons. Bloom F.E., Kupfer D.J. Psychopharmacology: the fourth generation of progress. 1995;227-243 Raven Press, New York.
51. Sheng M., Greenberg M.E. The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron. 4:1990;477-485.
52. Sora I., Hall F.S., Andrews A.M., Itokawa M., Li X.-F., Wei H.-B., Wichems C., Lesch K.-P., Murphy D.L., Uhl G.R. Molecular mechanisms of cocaine reward combined dopamine and serotonin transporter knockouts eliminate cocaine place preference . Proc Natl Acad Sci USA. 98:2001;5300-5305.
53. Sora I., Wichems C., Takahashi N., Li X.-F., Zeng Z., Revay R., Lesch K.-P., Murphy D.L., Uhl G.R. Cocaine reward models conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice . Proc Natl Acad Sci USA. 95:1998;7699-7704.
54. Swanson J., Castellanos F.X., Murias M., LaHoste G., Kennedy J. Cognitive neuroscience of attention deficit hyperactivity disorder and hyperkinetic disorder. Curr Opin Neurobiol. 8:1998;263-271.
55. Swanson L.W. Cerebral hemisphere regulation of motivated behavior (1). Brain Res. 886:2000;113-164.
56. Taylor D., Ho B.T. Comparison of inhibition of monoamine uptake by cocaine, methylphenidate, and amphetamine. Res Commun Chem Pathol Pharmacol. 21:1978;67-75.
57. Waldman I.D., Rowe D.C., Abramowitz A., Kozel S.T., Mohr J.H., Sherman S.L., Cleveland H.H., Sanders M.L., Gard J.M.C., Stever C. Association of linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children heterogeneity owing to diagnostic subtype and severity . Am J Hum Genet. 63:1998;1767-1776.
58. Wetsel W.C., Khan W., Merchenthaler I., Rivera H., Halpern E.E., Phung H.M., Negro-Vilar A., Hannun Y.A. Tissue and cellular distribution of the extended family of protein kinase C isoenzymes. J Cell Biol. 117:1992;121-133.
59. Wirtshafter D. A comparison of the patterns of striatal Fos-LI induced by various dopamine agonists in rats. Neurosci Lett. 289:2000;99-102.
60. Woolverton W.L., Johnson K.M. Neurobiology of cocaine abuse. Trends Pharmacol Sci. 13:1992;193-200.
61. Zametkin A.J., Liebenauer L.L., Fitzgerald G.A., King A.C., Minkunas D.V., Herscovitch P., Yamada E.M., Cohen R.M. Brain metabolism in teenagers with attention deficit hyperactivity disorder. Arch Gen Psychiatry. 50:1993;333-340.